Tay S K, Lai F M, Soh L T, Ho T H, Ang P T, Au E
Department of Obstetrics and Gynaecology, Singapore General Hospital.
Aust N Z J Obstet Gynaecol. 1992 Aug;32(3):263-6. doi: 10.1111/j.1479-828x.1992.tb01962.x.
Combined cisplatin, ifosfamide and bleomycin (PIB) chemotherapy was given to 14 (11 recurrent and 3 advanced and metastatic) cervical carcinoma patients. At least 2 cycles of chemotherapy were given before assessment of tumour response. The overall response rate was 28.6%; the complete response rate was 14.3%. Sites of response included cervical lymph nodes and the lung. Toxicity was common. Alopecia was universal. Other toxicity included suppression of haematopoiesis (73%), leucopenia (71%) and nausea and vomiting. Two patients died from sepsis during the myelosuppressive phase. The role of PIB in the management of advanced and recurrent carcinoma of the cervix should be evaluated in a randomized-controlled trial.
对14例（11例复发、3例晚期及转移性）宫颈癌患者给予顺铂、异环磷酰胺和博来霉素联合化疗（PIB方案）。在评估肿瘤反应前至少给予2个周期的化疗。总缓解率为28.6%；完全缓解率为14.3%。缓解部位包括宫颈淋巴结和肺部。毒性反应常见。脱发普遍存在。其他毒性反应包括造血抑制（73%）、白细胞减少（71%）以及恶心和呕吐。2例患者在骨髓抑制期死于败血症。PIB方案在晚期和复发性宫颈癌治疗中的作用应通过随机对照试验进行评估。
